Prospects of Hyaluronidase Therapy in Novel COVID-19 Infection with Damage to Lungs
- 作者: Solov’yeva A.1, Korshunova L.2, Shurpo E.3, Namestnikova A.4
-
隶属关系:
- Ryazan State Medical University
- ФГБОУ ВО РязГМУ Минздрава России
- ФГБОУ ВО РязГМУ Минздрава России ГБУ РО ГК БСМП
- ГБУ РО ГК БСМП, Рязань, Россия
- 期: 卷 30, 编号 3 (2022)
- 页面: 313-322
- 栏目: Original study
- URL: https://journals.rcsi.science/pavlovj/article/view/101242
- DOI: https://doi.org/10.17816/PAVLOVJ101242
- ID: 101242
如何引用文章
详细
INTRODUCTION: In recent years, the production and regulation of synthesis of hyaluronic acid in COVID-19 has been actively studied. Hyaluronan plays a significant role in development of severe lung damage in COVID-19 and is a potential therapeutic target the action on which will probably improve prognosis for patients with COVID-19.
AIM: To study prospects of using bovhyaluronidaze azoximer in complex treatment of patients with COVID-19 with lung damage at the inpatient stage.
MATERIALS AND METHODS: Thirty five patients (6 men and 29 women) aged 58.9 ± 12.9 years hospitalized with COVID-19 infection, were examined. Capillary blood saturation (SpO2) was 80.1 ± 8.6%, the volume of lung damage in X-ray computed tomography (X-ray CT) was 45.1 ± 19.4% on the right and 40.0 ± 19.5% on the left. All the patients received treatment according to the “Temporary Guidelines: prevention, diagnosis and treatment of novel coronavirus infection. Ver. 14 (27.12.2021)”. Besides, as part of complex treatment for COVID-19, bovhyaluronidaze azoximer was administered intramuscularly on the 21.9 ± 6.8th day of illness with a course of 10 injections (once in 3 days).
RESULTS: In the course of comprehensive treatment including bovhyaluronidaze azoximer, increase in SpO2 was recorded: in 7 patients ― after 1 injection (4.2 ± 1.7%), in 24 ― after 2 injections (5.4 ± 0.6%), another 4 patients did not show any significant increase in SpO2 after the first two injections. Increase in SpO2 after the 1st injection inversely correlated with age (r = -0.34; p < 0.05) and the initial saturation (r = -0.38; p < 0.05). Increase in SpO2 after the second injection correlated with the day of illness on which treatment with bovhyaluronidaze azoximer began (r = -0.36; p < 0.05).
CONCLUSION: Use of bovhyaluronidaze azoximer in complex treatment for COVID-19 with the lung damage at the inpatient stage can be effective in younger patients with more expressed initial reduction of SpO2, and also in case of administration of the drug in the early stages of the disease. The data obtained in the pilot study, dictate the necessity of studying the level of hyaluronic acid in blood of patients with COVID-19 and lung damage and its role in risk stratification of such patients.
作者简介
Aleksandra Solov’yeva
Ryazan State Medical University
编辑信件的主要联系方式.
Email: savva2005@bk.ru
ORCID iD: 0000-0001-7896-6356
SPIN 代码: 1943-7765
MD, Dr. Sci. (Med.), Associate Professor
俄罗斯联邦, RyazanLudmila Korshunova
ФГБОУ ВО РязГМУ Минздрава России
Email: post_luda@mail.ru
ORCID iD: 0000-0003-0945-0772
SPIN 代码: 4694-3605
доцент, кандидат медицинских наук, доцент кафедры факультетской терапии имени профессора В.Я.Гармаша
главный внештатный специалист-пульмонолог Министерства Здравоохранения Рязанской области
俄罗斯联邦Ekaterina Shurpo
ФГБОУ ВО РязГМУ Минздрава РоссииГБУ РО ГК БСМП
Email: shurpo_87@mail.ru
SPIN 代码: 9242-2880
Researcher ID: AAF-6813-2022
кандидат медицинских наук, доцент кафедры факультетской терапии имени профессора В.Я.Гармаша
заместитель главного врача по клинико-диагностической работе ГБУ РО ГК БСМП
俄罗斯联邦Anastasia Namestnikova
ГБУ РО ГК БСМП, Рязань, Россия
Email: asik1402@yandex.ru
Researcher ID: AAЕ-9185-2022
врач-терапевт отделения № 5 для взрослого населения с коронавирусной инфекцией
参考
- Ng CK, Chan JWM, Kwan TL, et al. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax. 2004;59(10):889–91. doi: 10.1136/thx.2004.023762
- Xie L, Liu Y, Fan B, et al. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respiratory Research. 2005;6(1):5. doi: 10.1186/1465-9921-6-5
- Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian Journal of Radiology & Imaging. 2017;27(3):342–9. doi: 10.4103/ijri.IJRI_469_16
- Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Research. 2020;8:8. doi: 10.1038/s41413-020-0084-5
- Ojo AS, Balogun SA, Williams OT, et al. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulmonary Medicine. 2020;2020:6175964. doi: 10.1155/2020/6175964
- Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: hostdirected therapies should be an option. Lancet. 2020;395(10224):e35–6. doi: 10.1016/S0140-6736(20)30305-6
- Vasarmidi E, Tsitoura E, Spandidos DA, et al. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Experimental and Therapeutic Medicine. 2020;20(3):2557–60. doi: 10.3892/etm.2020.8980
- Tale S, Ghosh S, Meitei SP, et al. Post COVID-19 pneumonia pulmonary fibrosis. QJM. 2020;113(11):837–8. doi: 10.1093/qjmed/hcaa255
- Kligerman SJ, Franks TJ, Galvin JR. From the radiologic pathology archives: organization and fibrosis as a response to lung injury in diffuse alveolar damage, organizing pneumonia, and acute fibrinous and organizing pneumonia. Radiographics. 2013;33(7):1951–75. doi: 10.1148/rg.337130057
- George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet. Respiratory Medicine. 2020;8(8):807–15. doi: 10.1016/S2213-2600(20)30225-3
- Han X, Fan Y, Alwalid O, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299(1):E177–86. doi: 10.1148/radiol.2021203153
- Wong K–T, Antonio GE, Hui DSC, et al. Severe acute respiratory syndrome: thin-section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. Journal of Computer Assisted Tomography. 2004;28(6):790–5. doi: 10.1097/00004728-200411000-00010
- Liu C, Ye L, Xia R, et al. Chest Computed Tomography and Clinical Follow-Up of Discharged Patients with COVID-19 in Wenzhou City, Zhejiang, China. Annals of the American Thoracic Society. 2020;17(10):1231–7. doi: 10.1513/AnnalsATS.202004-324OC
- Ding M, Zhang Q, Li Q, et al. Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19. Respiratory Medicine. 2020;167:105981. doi: 10.1016/j.rmed.2020.105981
- Hellman U, Karlsson MG, Engström–Laurent A, et al. Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options? The Journal of Biological Chemistry. 2020;295(45):15418–22. doi: 10.1074/jbc.AC120.015967
- Queisser KA, Mellema RA, Middleton EA, et al. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight. 2021;6(17):e147472. doi: 10.1172/jci.insight.147472
- Ontong P, Prachayasittikul V. Unraveled roles of hyaluronan in severe COVID-19. EXCLI Journal. 2021;20:117–25. doi: 10.17179/excli2020-3215
- Hällgren R, Samuelsson T, Laurent TC, et al. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. The American Review of Respiratory Disease. 1989;139(3):682–7. doi: 10.1164/ajrccm/139.3.682
- Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory Medicine. 2020;8(4):420–2. doi: 10.1016/S2213-2600(20)30076-X
- Bell TJ, Brand OJ, Morgan DJ, et al. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biology. 2019;80:14–28. doi: 10.1016/j.matbio.2018.06.006
- Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death and Differentiation. 2020;27(5):1451–4. doi: 10.1038/s41418-020-0530-3
- McKallip RJ, Ban H, Uchakina ON. Treatment with the hyaluronic Acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation. 2015;38(3):1250–9. doi: 10.1007/s10753-014-0092-y
- Nekrasov AV, Ivanova AS, Puchkova NG. Longidaza ― sovremennyj podhod v lechenii zabolevanij, soprovozhdayushchihsya giperplaziej soedinitel'noj tkani. Signatura. 2006;(1):43–52. (In Russ).
- Chernyavskaya OA, Osipov AV. Pathogenetic bases of the use of antifibrotic therapy with Bovhyaluronidazum azoximerum in patients with new coronavirus infection COVID-19. Medical Council. 2021;(12):154–60. (In Russ). doi: 10.21518/2079-701X-2021-12-154-160
- Vremennyye metodicheskiye rekomendatsii: profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). Versiya 14 (27.12.2021). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/%D0%92%D0%9C%D0%A0_COVID-19_V14_27-12-2021.pdf. Accessed: 2022 February 20. (In Russ).
- Kotova NV, Polyanskiy AV. Chto delat’ s patsiyentom, perenesshim COVID-pnevmoniyu? Opyt klinicheskogo ispol’zovaniya bovgialuronidazy azoksimer (longidazy) dlya profilaktiki i lecheniya post-kovidnogo fibroza legkikh. Glavnyy Vrach Yuga Rossii. 2021;(4):11–2. (In Russ).
- Zabozlaev F.G., Kravchenko E.V., Gallyamova A.R., et al. Pulmonary pathology of the new coronavirus disease (COVID-19). The preliminary analysis of post-mortem findings. Journal of Clinical Practice. 2020;11(2):21–37. (In Russ). doi: 10.17816/clinpract34849